Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Poseida Therapeutics, Inc. | Chief Medical Officer | Common Stock | 185K | $764K | $4.13 | Apr 1, 2024 | Direct |
Caribou Biosciences, Inc. | Chief Medical Officer | Option to purchase Common Stock | 131K | $352K | $2.69 | Feb 21, 2023 | Direct |
Poseida Therapeutics, Inc. | Chief Medical Officer | Employee Stock Option (Right to Buy) | 250K | Apr 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PSTX | Poseida Therapeutics, Inc. | Apr 1, 2024 | 2 | $0 | 4 | Apr 3, 2024 | Chief Medical Officer |
PSTX | Poseida Therapeutics, Inc. | Apr 1, 2024 | 0 | $0 | 3 | Apr 3, 2024 | Chief Medical Officer |
CRBU | Caribou Biosciences, Inc. | Feb 21, 2023 | 1 | $0 | 4 | Feb 23, 2023 | Chief Medical Officer |
CRBU | Caribou Biosciences, Inc. | Jan 19, 2023 | 1 | -$35.5K | 4 | Jan 20, 2023 | Chief Medical Officer |
CRBU | Caribou Biosciences, Inc. | Jan 25, 2022 | 2 | $0 | 4 | Jan 25, 2022 | Chief Medical Officer |
CRBU | Caribou Biosciences, Inc. | Jan 18, 2022 | 0 | $0 | 3 | Jan 24, 2022 | Chief Medical Officer |